increasingly popular technique for reviewing the results of clinical trials in drug development is pharmacometrics modelling. This chapter focuses on pharmacometrics' theoretical and applied elements. It begins by outlining the fundamental elements of pharmacometrics. The reasoning for the pharmacometrics analysis is then thoroughly reviewed. This includes developing the engineering-based dynamic processes that define the system under consideration, which are obtained by translating biological processes into a mathematical framework; using nonlinear mixed-effect modelling as the statistical modelling approach to define the distribution of the model parameters (pharmacokinetics (PK)/pharmacodynamics (PD)); formulating the model; and using optimization techniques, such as the Monte Carlo expectation maximisation algorithm.
Vladlen Slepak
University of Miami, United States
Axel H Schonthal
University of Southern California, United States
Consolato M Sergi
University of Alberta, Canada
Huiqin Yang
ICON Clinical Research Ltd, United Kingdom
Madhav Bhatia
University of Otago, New Zealand
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, India
Lan Wang
Paretor LLC, United States
Helen Cho
Samyang Biopharm Corporation, Korea, Republic ofSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary